Outlook
- SIGA expects to deliver $13 mln of oral TPOXX to an international customer in Q2 2026
- Company plans to deliver $26 mln of IV TPOXX to U.S. Government by end of Q3 2026
- SIGA says focus remains on securing new procurement contracts and orders to drive business
Result Drivers
- INTERNATIONAL EXPANSION – Co signed exclusive license agreement for oral TPOXX in MENA region
- UPCOMING CONTRACT DELIVERIES – Co expects to deliver $13 mln of oral TPOXX to Asia Pacific customer in Q2 and $26 mln of IV TPOXX to U.S. government by end of Q3
Ticker: $SIGA
Sector: Healthcare
Industry: Pharmaceuticals
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company. The Company is focused on the development of medicines to treat and prevent infectious diseases. Its flagship product, TPOXX (tecovirimat), is an antiviral medicine approved in the United States and Canada for the treatment of smallpox and authorized in Europe, the United Kingdom, and Japan for the treatment of smallpox, monkeypox (mpox), cowpox, and vaccinia complications. TPOXX specifically inhibits the activity of a protein called VP37, found on the surface of all orthopoxviruses. This prevents the virus from leaving infected cells, slowing the spread of the infection and limiting it to a point where the immune system can clear the virus. The European Medicines Agency and United Kingdom approvals include labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox.
Headquarters31 East 62Nd Street
New York, NY
10065